Turning Cancer Cells into Allies, Moderna News, and Future Therapeutic Development
Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news.
Insilico Medicine Racks Up Wins, And Michael Torres Outlines Longevity Gene Therapy
Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before they become big news.
The Snake Molecule That Could Replace GLP-1s | The Jack Gugel Interview
Jack Gugel, co-founder and CEO of Arkana Therapeutics, joins the show to explain how a molecule discovered in Burmese python metabolism could offer an alternative to GLP-1 drugs, why pythons are the perfect model organism for studying extreme metabolic swings, and why he thinks every PhD should end with a company instead of a postdoc application. Arkana spun out of a University of Colorado Boulder lab that's spent 20 years studying how Burmese pythons survive a year without eating, then consume a meal…
Thursday, July 9th
Welcome to The Biotech Voyager. It's the show that covers the early-stage biotech space, uncovering the companies that are going to be a big deal in a couple of years.
iPSC Cells Get Attention, Gut Bug Clinical Readouts, and X-tosis
Welcome to the Biotech Voyager. It's the show that covers what's next in biotech. Drop a question in the chat to be part of the conversation .
The Kevin Walton Interview - Baseimmune
Kevin Walton, CEO of Baseimmune, joins Ben and Jeff to break down one of the most underappreciated problems in modern medicine: fibrosis. IPF alone carries a life expectancy of three to five years upon diagnosis, and despite decades of research only three drugs have been approved, none of which halt or reverse the disease. Kevin explains why every previous approach has failed, why fibrosis is a network-driven redundant disease that defeats single-target therapies, and how Baseimmune's computational…
The Jonathan Cohen-Gold Interview - CEO of Houdini Bio🧬
Jonathan Cohen-Gold, CEO of Houdini Bio, joins Ben and Jeff to break down one of the most underappreciated problems in cell and gene therapy: cells don't like foreign DNA. When you deliver a therapeutic gene, the cell's innate immune system recognizes it as a threat and shuts it down. Houdini Bio's platform uses AI and proprietary Houdini elements, short 100 base pair sequences, to give the therapeutic DNA a self-hallmark, essentially camouflaging it against the cell's defense machinery without touching…
A Vaccine for Scar Tissue? And Cancer Cells that Build Their Own Destruction?
Welcome to the Biotech Voyager. It's the live show that covers what's next in biotech. Today on the show: - 3 brand new startups in biotech that emerged from Stealth - 2 CEO interviews: one company is building a vaccine for tissue scarring, and the other, which just raised over $9M, turns solid tumors into therapeutic factories. Leave a comment if you have any questions - we try to get to them all!
Is Non-Viral Gene Therapy About to Kill AAV?
YouTube Description: Non-viral gene delivery has always had one fatal flaw: it couldn't get DNA into the nucleus efficiently. LNPs top out at around 5% nuclear entry. SonoThera just hit 50% using ultrasound. Co-founder Ken Greenberg joins the show to break down exactly how they did it. We also cover AstroRx's embryonic stem cell-derived astrocyte therapy for MS, ANACA's TCR-T cell approach for solid tumors, Apligon's next-gen kinase inhibitor program, and Enterome's microbiome-based cancer therapy, plus…
3D Tissue Printing in SPACE & The Rise of Protein Degraders
Welcome to The Biotech Voyager. It's the live show that covers where the puck is going in biotech.
Cancer Therapeutics Roar, and the Founders of Tolemy Bio (and VelociTx) Join the Show
Welcome to The Biotech Voyager. It's the show that covers what's next in biotech.